US2017273934A1PendingUtilityA1

Treatment of Triple Receptor Negative Breast Cancer

50
Assignee: SYNCORE BIOTECHNOLOGY CO LTDPriority: Mar 22, 2006Filed: Jun 12, 2017Published: Sep 28, 2017
Est. expiryMar 22, 2026(expired)· nominal 20-yr term from priority
Inventors:Kay-Oliver KlicheAxel MeschederMartine Piccart
A61P 35/00A61K 9/127A61K 45/06A61K 9/1272A61K 31/337A61K 2300/00
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the use of a liposomal preparation for the manufacture of a pharmaceutical composition and the use of such a composition for the treatment of “triple receptor negative” breast cancer.

Claims

exact text as granted — not AI-modified
1 . The use of a cationic liposomal preparation comprising at least one cationic lipid, an antimitotic agent and optionally at least one neutral and/or anionic lipid for the manufacture of a pharmaceutical composition for the treatment of triple receptor negative breast cancer in a human or animal. 
     
     
         2 - 32 . (canceled)

Join the waitlist — get patent alerts

Track US2017273934A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.